Health Boards
Another bio in the pipeline, risankizumab an IL-23 inhibitor by AbbVie will have data presented at the 25th European Academy of Dermatology and Venereology Congress (EADV), September 28 - October 2, in Vienna, Austria. They will also be presenting new data on Humira.
Source: abbvie.com
Quote:
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that new data on HUMIRA® (adalimumab) and investigational medicine risankizumab (formerly BI 655066), an IL-23 inhibitor, will be presented at the 25th European Academy of Dermatology and Venereology Congress (EADV), September 28 - October 2, in Vienna, Austria. These presentations build upon AbbVie's continued scientific leadership in serious dermatological conditions including psoriasis, psoriatic arthritis and hidradenitis suppurativa.
"AbbVie's presence at EADV 2016 highlights the latest scientific research in difficult-to-treat skin conditions, including data underscoring the considerable impact these diseases can have on a person's physical, social and emotional wellbeing and the need for quality care," said Shao-Lee Lin, Vice President Therapeutic Areas and International Development, AbbVie. "Additionally, building on our deep experience over more than 18 years in immunology with HUMIRA, we are excited to present the latest results of data evaluating investigational compound risankizumab, an IL-23 biologic for patients living with moderate to severe chronic plaque psoriasis."
New data from studies evaluating investigational IL-23 monoclonal biologic antibody, risankizumab, will be presented from the Phase 2 open-label extension study in moderate to severe chronic plaque psoriasis.
AbbVie will also present HUMIRA two-year safety and efficacy results for the treatment of moderate to severe HS, as well as multiple health economics outcomes research studies revealing the real-world burden of HS on patients and demonstrating AbbVie's commitment to the underserved HS community. Further, new seven year interim results from the ESPRIT 10-year post-marketing surveillance safety registry of HUMIRA will report safety and effectiveness of HUMIRA treatment for moderate to severe chronic plaque psoriasis.
Source: abbvie.com
